AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, K. R
Right arrow Articles by Failla, M. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, K. R
Right arrow Articles by Failla, M. L
Agricola
Right arrow Articles by Walsh, K. R
Right arrow Articles by Failla, M. L
American Journal of Clinical Nutrition, Vol. 85, No. 4, 1050-1056, April 2007
© 2007 American Society for Nutrition

ORIGINAL RESEARCH COMMUNICATION

Isoflavonoid glucosides are deconjugated and absorbed in the small intestine of human subjects with ileostomies1,2,3

Kelly R Walsh, Sara J Haak, Torsten Bohn, Qingguo Tian, Steven J Schwartz and Mark L Failla

1 From the Interdisciplinary PhD Program in Nutrition (KRW, SJS, and MLF), the Department of Human Nutrition (SJH and MLF), and the Department of Food Science (TB, QT, and SJS), The Ohio State University, Columbus, OH

Background:Although soy isoflavonoids have a number of health-promoting benefits, information concerning the sites of their absorption and metabolism in humans remains limited. Isoflavonoid absorption from the gut requires deconjugation of glucosides to aglycones.

Objective:The objective was to investigate the role of the small intestine in isoflavonoid absorption and metabolism in humans.

Design:Human subjects with fully functional gastrointestinal tracts (n = 6) and ileostomy subjects (n = 6) were fed a single soy meal containing 64.8 mg isoflavonoid aglycone equivalents (95% as glucosides). Metabolism of isoflavonoids in the upper gastrointestinal tract was examined by analyzing ileal effluent from ileostomy subjects, and absorption was assessed indirectly by quantifying isoflavonoids and several metabolites in 24-h urine pools.

Results:Chyme contained 36.7% of ingested isoflavonoid aglycone equivalents, primarily (95.8%) as aglycones. Qualitative profiles (x ± SEM) of isoflavonoid excretion in urine (daidzein > glycitein > genistein) and the quantity of isoflavonoid equivalents were not significantly different between the control (18.4 ± 2.2 mg) and ileostomy (13.5 ± 3.2 mg) subjects. Dihydrodaidzein was present in the urine of all subjects, although the amount excreted by ileostomy subjects was less than that excreted by the control subjects. The percentage of producers and mean quantities of dihydrogenistein, equol, and O-desmethylangolensin in the urine of ileostomy subjects also were lower than those of control subjects.

Conclusions:Ileostomy subjects efficiently deglycosylate isoflavonoid glucosides in the small intestine and appear to absorb aglycones with an efficiency comparable with that of control subjects. However, the production of microbial metabolites of isoflavonoids is limited in ileostomy subjects.

Key Words: Soy isoflavonoids • isoflavonoid absorption • ileostomy • small intestine • equol • dihydrodaidzein • dihydrogenistein • O-desmethylangolensin






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The American Society for Nutrition